Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 11, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Approaching Ewing sarcoma.

Uta Dirksen1, Heribert Jürgens

  • 1Pediatric Hematology & Oncology, Albert-Schweitzer Str. 33, 48149 Münster, Germany.

Future Oncology (London, England)
|July 14, 2010
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of standardized uptake value (SUV) and apparent diffusion coefficient (ADC) as prognostic imaging parameters for primary Ewing sarcoma in hybrid 18F-FDG-PET/MRI.

European journal of radiology·2026
Same author

Diagnostic value of integrated 18F-fluorodeoxyglucose PET/MRI in initial staging and recurrence detection of Ewing sarcoma.

Nuclear medicine communications·2026
Same author

Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial.

The Lancet. Haematology·2026
Same author

Treatment effect heterogeneity of radiotherapy in localized Ewing sarcoma: A secondary analysis of the EURO-E.W.I.N.G. 99 and Ewing 2008 trial.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Potential biomarkers of Ewing sarcoma identified through a Europe-wide analysis of prospectively collected samples.

Scientific reports·2026
Same author

Elimusertib enhances cytotoxic effects of conventional chemotherapy and sensitizes to radiation in preclinical Ewing sarcoma models.

Scientific reports·2026
Same journal

Plain language summary of the MiroCIP study: how often chemotherapy-induced peripheral neuropathy happens in the first year of oxaliplatin- or taxane-based chemotherapy.

Future oncology (London, England)·2026
Same journal

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.

Future oncology (London, England)·2026
Same journal

How enzalutamide affects sex life and how taking a break from treatment affects quality of life: a plain language summary of results from the EMBARK study in people with hormone-sensitive prostate cancer and high-risk biochemical recurrence.

Future oncology (London, England)·2026
Same journal

Physician perspectives on the decision-making process for patients with high-risk early-stage triple-negative breast cancer in a community oncology setting.

Future oncology (London, England)·2026
Same journal

Healthcare resource utilization and economic burden of metastatic pancreatic cancer: a US commercial and Medicare claims analysis.

Future oncology (London, England)·2026
Same journal

Disparities in mortality among HER2-positive breast cancer patients treated with trastuzumab in Chile (2015-2024): real-world evidence from 4,920 cases.

Future oncology (London, England)·2026
See all related articles

Ewing sarcoma research focuses on its unique EWS-ETS genetic driver. While multimodal treatments improve survival, a high relapse rate necessitates novel therapeutic strategies for this rare childhood cancer.

Area of Science:

  • Pediatric Oncology
  • Molecular Oncology
  • Cancer Genetics

Background:

  • Ewing sarcoma is a rare pediatric malignancy characterized by a specific EWS-ETS gene translocation.
  • This translocation results in a fusion protein that significantly alters intracellular signaling pathways.
  • Despite advances, current treatments have not fully overcome the challenges posed by this complex cancer.

Purpose of the Study:

  • To provide an overview of recent advancements in Ewing sarcoma research.
  • To highlight potential therapeutic strategies with translational value.
  • To address the persistent challenge of high relapse rates in Ewing sarcoma.

Main Methods:

  • Review of current literature on Ewing sarcoma research.
  • Analysis of molecular mechanisms, including the EWS-ETS translocation.

More Related Videos

Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts
07:50

Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts

Published on: May 25, 2018

Related Experiment Videos

Last Updated: Jun 11, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts
07:50

Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts

Published on: May 25, 2018

  • Evaluation of multimodal treatment approaches and their outcomes.

    • Main Results:

    • Multimodal treatments, including chemotherapy and local therapy, have improved prognosis up to 70%.
    • Survival rates have plateaued for over a decade, indicating a need for further progress.
    • A significant 30% relapse rate remains a critical issue, with poor outcomes post-relapse.

    Conclusions:

    • Novel therapeutic approaches are urgently needed to improve outcomes for Ewing sarcoma patients.
    • Understanding the molecular underpinnings, particularly the EWS-ETS fusion, is key to developing targeted therapies.
    • Continued research into translational strategies holds promise for overcoming treatment resistance and reducing relapse rates.